Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 3
2014 2
2016 1
2017 1
2018 7
2019 3
2021 2
2022 9
2023 8
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.
Ichikawa H, Yakushijin K, Kurata K, Tsuji T, Takemoto N, Joyce M, Okazoe Y, Takahashi R, Matsumoto S, Sakai R, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Ichikawa H, et al. Among authors: miyata y. Bone Marrow Transplant. 2024 Apr;59(4):518-525. doi: 10.1038/s41409-024-02215-4. Epub 2024 Jan 29. Bone Marrow Transplant. 2024. PMID: 38287083 Free PMC article.
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakamura N, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Nakajima TE. Murakami M, et al. Among authors: miyata y. Int J Clin Oncol. 2025 Jan;30(1):27-39. doi: 10.1007/s10147-024-02663-4. Epub 2024 Nov 21. Int J Clin Oncol. 2025. PMID: 39570460
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.
Hayashi T, Yamamoto S, Miyata Y, Takeda M, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iihara H. Hayashi T, et al. Among authors: miyata y. Int J Clin Oncol. 2024 Nov;29(11):1616-1631. doi: 10.1007/s10147-024-02623-y. Epub 2024 Sep 11. Int J Clin Oncol. 2024. PMID: 39259324
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.
Imamura Y, Otsui K, Mori K, Kitagawa K, Okada H, Hata A, Hayashi H, Nose T, Ohata S, Miyata Y, Funakoshi Y, Toyoda M, Yakushijin K, Kiyota N, Matsuoka H, Minami H. Imamura Y, et al. Among authors: miyata y. Int J Hematol. 2022 Apr;115(4):499-507. doi: 10.1007/s12185-022-03289-w. Epub 2022 Jan 25. Int J Hematol. 2022. PMID: 35079961 Clinical Trial.
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Ichikawa H, Sakai H, Hojo W, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Watanabe M, et al. Among authors: miyata y. Vaccines (Basel). 2022 Oct 29;10(11):1830. doi: 10.3390/vaccines10111830. Vaccines (Basel). 2022. PMID: 36366338 Free PMC article.
36 results